DaVita Inc. DVA
Composite 53/100; the shares have moved about 48% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Balance-sheet strength ranks 36/100 — a moderate mark against it.
Valuation ranks 67/100 — a moderate point in its favour. Quality ranks 64/100 — a moderate point in its favour. Momentum ranks 57/100 — a slight point in its favour.
Balance-sheet strength ranks 36/100 — a moderate mark against it. Growth ranks 36/100 — a moderate mark against it.
What the company does DaVita Inc. operates kidney dialysis centers and related lab services in the U.S., serving patients with chronic kidney failure. Its offerings include outpatient, inpatient, and home-based hemodialysis, clinical labs, integrated care services, and transplant software.
Key financials DaVita reports strong profitability metrics: ROE 88.5%, ROA 7.5%, ROCE 13.8%, and net margin 6.0%. Revenue growth is 6.5%, but EPS declined -14.6%. Liquidity is adequate (current ratio 1.47), though leverage is high (Debt/Equity 12.42).
Stock health Momentum is mixed: -7.63% over 3 months but +20.43% over 6 months and +31.11% over 12 months. The stock is -27.25% below its 52-week high, with RSI(14) at 33.60, indicating oversold conditions.
Price vs fair value The stock trades at a **discount of 21.30%** to the analyst mean target of 218.43. - Partnership with Humana expands value-based care for 10,000+ patients (InvestorsHub) - Analysts highlight potential margin pressures in Medicare Advantage (Simply Wall St.) - Value-based care expansion cited as a growth driver (Zacks)
Looking forward Forward P/E of 12.66 and PEG of 0.59 suggest attractive valuation relative to growth. Sideravia’s overall score of 53.4 reflects average quality but strong valuation metrics.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.